Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.
about
Extended-spectrum beta-lactamases: a clinical updateCarbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control.Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries.Wide dissemination of extended-spectrum β-lactamase-producing Escherichia coli in community residents in the Indochinese peninsulaDiversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study.Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.High prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar.Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital.Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health regionRectal carriage of extended-spectrum beta-lactamase-producing gram-negative bacilli in community settings in MadagascarPrevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection.Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting.Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.Proportion of extended-spectrum ß-lactamase-producing Enterobacteriaceae in community setting in Ngaoundere, Cameroon.Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study.In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.Varying high levels of faecal carriage of extended-spectrum beta-lactamase producing Enterobacteriaceae in rural villages in Shandong, China: implications for global health.Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutionsRisk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country.Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. an exploratory case-control study.Extended-spectrum beta-lactamase-producing Gram-negative bacteria causing neonatal sepsis in India in rural and urban settings.Impact of extended-spectrum β-lactamase production on treatment outcomes of acute pyelonephritis caused by escherichia coli in patients without health care-associated risk factors.Prevalence and characteristics of extended-spectrum β-lactamase and plasmid-mediated fluoroquinolone resistance genes in Escherichia coli isolated from chickens in Anhui province, ChinaIs antibiotic resistance a problem? A practical guide for hospital clinicians.Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal.Emergence of community-acquired extended-spectrum beta-lactamase Escherichia coli (ESBLEC) in Honolulu: a case series of three individuals with community-acquired ESBLEC bacteriuriaAn outbreak of multi-drug resistant Escherichia coli urinary tract infection in an elderly population: a case-control study of risk factors.Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors.Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular EpidemiologySimultaneous gut colonisation and infection by ESBL-producing Escherichia coli in hospitalised patientsEmergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community.Prevalence, Risk Factors, and Transmission Dynamics of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: a National Survey of Cattle Farms in Israel in 2013.Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.Characterization of CTX-M-Type Extend-Spectrum β-Lactamase Producing Klebsiella spp. in Kashan, Iran.The search for new antimicrobials: why we need new options.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Risk Factor Analysis in Clinical Isolates of ESBL and MBL (Including NDM-1) Producing Escherichia coli and Klebsiella Species in a Tertiary Care HospitalThe erratic antibiotic susceptibility patterns of bacterial pathogens causing urinary tract infections.
P2860
Q24534999-C542FC1A-2494-4147-949D-BCC8DD2D8336Q30148824-BF0EAEFB-091C-4DBA-B698-564E48533D43Q30358381-4A7B8E95-AEE1-4133-A65B-DFB98E254337Q30389643-2CEE5B8C-53D4-4D13-A55E-4EE7677F554FQ30389929-A163EC44-E800-48FD-8EFA-D30B6FC11196Q33601794-FF2F3B0F-8926-4183-949D-A70FEF007D92Q33630862-32DD8F7A-A613-4AA9-B037-CCBA98187D15Q33791265-72E05BA3-F9AB-4893-A593-92BA577D03ECQ33856392-EFA48809-3459-4293-9BEB-16F5F70DD0CFQ33987808-0AD9471F-B3B7-42A3-8768-91726344338AQ34009487-6708F7F8-6B0F-46FD-B42F-523129DDCB0FQ34027016-F450C064-3C10-481D-B241-49E37D0D7136Q34073299-FD7C59A0-C741-4157-BC7F-509C4D21CB0BQ34108669-C5F7DA93-67E3-4A3E-8650-69808E1A945FQ34190353-D38E550A-5D5C-4E3B-AF53-36E5C78615D4Q34269727-339A3556-EE7D-412E-BF04-6F86A31F58ECQ34301565-319FCE5A-C8BB-492D-B935-FCE33E7FC495Q34535865-844E7D3B-BE1B-4BB7-BB3D-9376CD0BF149Q34720052-157F42DA-96ED-4D38-A0AF-B767DF70934BQ34920553-B22AFF0A-D1E0-4B76-B189-0FEC943EE0CBQ34989958-87C52702-D014-457C-8E71-4B448524C265Q35097441-746B5A6F-84C0-4300-9919-06EC17479682Q35168939-738C20AE-7278-43FC-8B60-27FED3AA0AA5Q35228750-28818233-7323-45BD-9D28-2A8896CF9077Q35523222-13E9875F-4B77-4904-ACF7-D090400188E5Q35559648-8D5A766A-7F61-44B1-AA8C-B0A5BAA73B54Q35600060-1615CB66-18AF-42CC-94A3-877884A89C36Q35657200-C3657E1D-7BBE-4E90-8949-64F480B2340DQ35690327-858C11C2-1D45-4C59-9D27-7AF3EFA9C913Q35690509-78C5D157-B63B-4B8E-8C26-E75BD191E15CQ35735182-D18FE81B-FC70-4BFD-B638-C04B4528AE6AQ35834058-67E15BCD-9377-4F59-A4AA-F51F42BD4C6EQ36139832-4929FC80-54B5-4CE4-835D-E475C62C635BQ36174026-333D950E-8782-4657-AADF-41ECE0A80638Q36277409-0F5CBD8E-2889-4D64-8532-EAB5F18CBC44Q36278614-09AAB250-AD31-402C-A8AA-4F65D965AFF7Q36322113-E5592D08-EA27-4A3D-9071-62FB2059F491Q36337074-BD485545-F1D3-4269-81A3-896975E068B6Q36343438-7BAE9585-D242-488D-A389-30E344C23912Q36347562-4505C0EF-6B7F-4732-8D5D-681C9AF27114
P2860
Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Epidemiology and clinical feat ...... i in nonhospitalized patients.
@ast
Epidemiology and clinical feat ...... i in nonhospitalized patients.
@en
type
label
Epidemiology and clinical feat ...... i in nonhospitalized patients.
@ast
Epidemiology and clinical feat ...... i in nonhospitalized patients.
@en
prefLabel
Epidemiology and clinical feat ...... i in nonhospitalized patients.
@ast
Epidemiology and clinical feat ...... i in nonhospitalized patients.
@en
P2093
P2860
P1476
Epidemiology and clinical feat ...... li in nonhospitalized patients
@en
P2093
Alvaro Pascual
Evelio J Perea
Luisa Romero
Maria Dolores Navarro
Miguel A Muniain
Ramón Pérez-Cano
P2860
P304
P356
10.1128/JCM.42.3.1089-1094.2004
P407
P577
2004-03-01T00:00:00Z